Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (281-290 of 490) with videos related to

Pageof 49
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Proteomics. Clinical Applications|December 8, 2010
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approachBalwir Matharoo-Ball, Lucy Ratcliffe, Lee Lancashire, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Anti-Cancer Drugs|June 5, 2003
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility studyClaudia Pföhler, Ian A Cree, Selma Ugurel, et al.
Stem Cell Research|May 23, 2015
Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neuronsSandra Horschitz, Friederike Matthäus, Anja Groß, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Pigment Cell & Melanoma Research|April 24, 2016
TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cellsKasia Weina, Huizi Wu, Nathalie Knappe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 1, 2011
Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanomaDaniel Hausmann, Susanne Jochum, Jochen Utikal, et al.
Blood|December 17, 2005
Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathwayJulia Kzhyshkowska, Srinivas Mamidi, Alexei Gratchev, et al.
Cellular Immunology|December 31, 2020
Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot studyChristoffer Gebhardt, Sonja C S Simon, Rebekka Weber, et al.
Pageof 49

Showing results (281-290 of 490) with videos related to

Sort By:
Pageof 49
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Proteomics. Clinical Applications|December 8, 2010
Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approachBalwir Matharoo-Ball, Lucy Ratcliffe, Lee Lancashire, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trialLisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Anti-Cancer Drugs|June 5, 2003
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility studyClaudia Pföhler, Ian A Cree, Selma Ugurel, et al.
Stem Cell Research|May 23, 2015
Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neuronsSandra Horschitz, Friederike Matthäus, Anja Groß, et al.
European Journal of Cancer (Oxford, England : 1990)|June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesAnne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Pigment Cell & Melanoma Research|April 24, 2016
TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cellsKasia Weina, Huizi Wu, Nathalie Knappe, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 1, 2011
Comparison of the diagnostic accuracy of whole-body MRI and whole-body CT in stage III/IV malignant melanomaDaniel Hausmann, Susanne Jochum, Jochen Utikal, et al.
Blood|December 17, 2005
Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathwayJulia Kzhyshkowska, Srinivas Mamidi, Alexei Gratchev, et al.
Cellular Immunology|December 31, 2020
Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot studyChristoffer Gebhardt, Sonja C S Simon, Rebekka Weber, et al.
Pageof 49